|
News For BSX;BAC;ABT;JNJ From The Last 14 Days Check below for free stories on BSX;BAC;ABT;JNJ the last two weeks. |
|
|
| May 24, 2013 |
| 12:34 EDT |  | BAC | Bank of America seeking buyers for 40 branches, Bloomberg reports
 Subscribe for More Information |
|
| 07:54 EDT |  | JNJ | Johnson & Johnson drug business should maintain momentum, says Wells Fargo
After attending J&J's bi-annual pharmaceutical business review, Wells Fargo believes that the revenue generated by four of the company's new drugs could double from 2012 to 2015. The firm thinks the company's pharmaceutical unit has one of the best growth outlooks in the sector, and it keeps an Outperform rating on the stock. |
|
| 06:28 EDT | | JNJ | Johnson & Johnson price target raised to $94 from $88 at Leerink
Subscribe for More Information |
|
| May 23, 2013 |
| 10:08 EDT |  | JNJ | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:31 EDT |  | JNJ | Janssen expects to have more than 25 brand line extensions by 2017
Subscribe for More Information |
|
| 07:12 EDT | | BAC | Wall Street trying to use trade deals to weaken Dodd-Frank, Bloomberg reports
Subscribe for More Information |
|
| 06:29 EDT | | JNJ | Johnson & Johnson coverage assumed with an Underperform at Credit Suisse
Subscribe for More Information |
|
| 06:08 EDT | | BAC | On the Fly: Periodicals Wrap-Up
Subscribe for More Information |
|
| May 22, 2013 |
| 16:00 EDT |  | JNJ | Options Update; May 22, 2013
Subscribe for More Information |
|
| 12:22 EDT | | BSX | Boston Scientific says new data shows blood pressure reduction with Vessix
Boston Scientific reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented at the annual EuroPCR Scientific Program in Paris. Interim data highlights include: All patients underwent successful bilateral renal denervation treatment; At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure; No device-related adverse events or procedural renal artery complications were reported; Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available; Demonstrated success in treating various anatomies, including accessory renal arteries; Demonstrated short renal denervation procedural time. |
| |
| 10:44 EDT | | BSX | Boston Scientific says Lotus system met primary performance endpoint in trial
Subscribe for More Information |
|
| 09:35 EDT | | BSX | Boston Scientific says trials show 'exceptional' safety, efficacy data on stents
Boston Scientific reported positive results from two trials evaluating new, innovative drug-eluting stent technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element Stent System were presented at the annual EuroPCR Scientific Program in Paris. The primary investigator for one trial said, "The Promus PREMIER Stent demonstrated excellent safety and effectiveness with zero percent target lesion revascularization and stent thrombosis. In addition, the rate of technical success, the primary endpoint of the trial, was very high at 99.2%." |
|
| 09:02 EDT | | BAC | Financials upgraded to Overweight from Market Weight at Wells Fargo
Wells Fargo believes that financials' earnings continue to be the strongest of any sector in the S&P 500. The firm thinks that the sector's stocks appear to be breaking out from a technical standpoint. Citigroup (c) and Ameriprise Financial (AMP) are on the firm's priority list. |
|
| 07:28 EDT |  | ABT | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link |
|
| 07:22 EDT | | BAC | Dun & Bradstreet to hold a conference
2013 Access to Capital is being held in Chicago on May 22. |
|
| May 21, 2013 |
| 11:49 EDT | | BSX | Boston Scientific data show Bronchial Thermoplasty benefits for up to five years
Subscribe for More Information |
|
| 08:03 EDT | | ABT | Abbott announces CE Mark for coronary drug eluting stent
Subscribe for More Information |
|
| 07:24 EDT | | JNJ | Global Health Care to host a conference
Subscribe for More Information |
|
| 07:13 EDT | | BAC | U.S. bank mergers less likely this year, Bloomberg reports
Subscribe for More Information |
|
| 05:48 EDT | | BSX | OrbusNeich seizes Boston Scientific stents as part of patent infringement case
Subscribe for More Information |
| |
| May 20, 2013 |
| 10:11 EDT |  | BAC | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Artisan Partners (APAM) downgraded to Market Perform from Outperform at Keefe Bruyette... Bank of America (BAC) downgraded to Market Perform from Outperform at Keefe Bruyette... Bed Bath & Beyond (BBBY) downgraded to Hold from Buy at Jefferies... BlackRock (BLK) downgraded to Market Perform from Outperform at Keefe Bruyette... Cavium (CAVM) downgraded to Market Perform from Outperform at JMP Securities... Charles Schwab (SCHW) downgraded to Underperform from Market Perform at Keefe Bruyette... Dunkin' Brands (DNKN) downgraded to Neutral from Buy at Longbow... Equifax (EFX) downgraded to Neutral from Buy at Goldman... Leap Wireless (LEAP) downgraded to Sell from Hold at Deutsche Bank... Lowe's (LOW) downgraded to Perform from Outperform at Oppenheimer... MicroStrategy (MSTR) downgraded to Market Perform from Outperform at JMP Securities... NetApp (NTAP) downgraded to Underperform from Neutral at RW Baird... NeuStar (NSR) downgraded to Neutral from Buy at Goldman... Red Hat (RHT) downgraded to Market Perform from Outperform at BMO Capital... Ruby Tuesday (RT) downgraded to Market Perform from Outperform at Wells Fargo... Synovus (SNV) downgraded to Sell from Neutral at Goldman... TD Ameritrade (AMTD) downgraded to Underperform from Market Perform at Keefe Bruyette... Thoratec (THOR) downgraded to Neutral from Buy at Goldman... CF Industries (CF) downgraded to Hold from Buy at Miller Tabak... Children's Place (PLCE) downgraded at Susquehanna... CarMax (KMX) downgraded to Market Perform from Outperform at William Blair... SanDisk (SNDK) downgraded to Neutral from Buy at Nomura... Red Hat (RHT) downgraded at BMO Capital... Rex Energy (REXX) downgraded to Hold from Buy at Stifel... Range Resources (RRC) downgraded to Hold from Buy at Stifel... Kansas City Southern (KSU) downgraded to Sell from Hold at Stifel... Capella Education (CPLA) downgraded to Hold from Buy at Stifel. |
|
| 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:41 EDT | | BSX | Supreme Court agrees to hear Medtronic-Boston Scientific patent case
Reported by SCOTUSblog live blog of court orders and opinions. |
|
| 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. |
|
| 05:39 EDT | | BAC | Bank of America downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette downgraded Bank of America with a $13.50 price target citing valuation. |
|
| May 17, 2013 |
| 16:00 EDT | | BAC | Options Update; May 17, 2013
Subscribe for More Information |
|
| 10:20 EDT |  | BAC | Bank of America rises, levels to watch
Subscribe for More Information |
|
| 06:19 EDT | | JNJ | J&J to end sales of of metal-on-metal hip replacements, Bloomberg reports
Subscribe for More Information |
|
| May 16, 2013 |
| 16:13 EDT | | BSX | Vascular Solutions files patent infringement complaint against Boston Scientific
Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. |
|
| 07:51 EDT | | BSX | Boston Scientific price target raised to $12 from $9 at JMP Securities
JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. |
| |
| 07:28 EDT | | BSX | I/O Central to host a conference
Subscribe for More Information |
|
| 07:18 EDT | | BAC | Investors bet on banks hit by credit crisis, Bloomberg reports
Subscribe for More Information |
|
| 06:41 EDT | | BAC | Big banks to benefit from U.S. concession on derivatives, NY Times says
Subscribe for More Information |
|
| May 15, 2013 |
| 16:51 EDT | | JNJ | FDA approves Simponi to treat ulcerative colitis
Subscribe for More Information |
|
| 10:13 EDT | | BAC | Bank of America reports April card write-offs 4.55% vs. 4.33% last month
Subscribe for More Information |
|
| May 14, 2013 |
| 15:33 EDT | | BSX | Boston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. |
|
| 10:53 EDT | | BAC | Bank of America breakout continues, levels to watch
The breakout back above what was persistent resistance at the $12.50 area has now taken on a firmer bullish footing. Shares are trading at multi-year highs, last at $13.25. At that price, resistance is now at $13.56 and then at $13.84. Support is at $13.01. |
|
| 08:44 EDT | | BAC | Bank of America management to meet with Deutsche Bank
Subscribe for More Information |
|
| 08:33 EDT | | BAC | CFTC investigates swap contracts, FT reports
The Commodity Futures Trading Commission issued a “special call” asking Wall Street banks and other traders to provide documents that would prove recent derivatives transactions known as “exchanges of futures for swaps” were legal. Lawyers at the CFTC enforcement division are also scrutinizing the trades for possible violations. The probe is into the legitimacy of more than 1M energy and metals transactions by the biggest traders in commodities markets over the past two years.Reference Link |
|
| 06:19 EDT | | BAC | Brokerage firms see market share drop, competition increase, Bloomberg reports
Subscribe for More Information |
| |
| May 13, 2013 |
| 15:04 EDT | | BAC | Fed says large banks must submit midyear stress tests on July 5
Eighteen large U.S. bank holding companies are required to submit the results of their company-run, midyear stress tests to the Federal Reserve on July 5, the Federal Reserve said. The Dodd-Frank Wall Street Reform and Consumer Protection Act required that large bank holding companies and non-bank financial institutions that are designated for Federal Reserve supervision by the Financial Stability Oversight Council conduct two stress tests each year. In the midyear test, which is being conducted for the first time in 2013, each firm develops its own baseline, adverse, and severely adverse scenarios to best reflect its individual operations and risks. Each firm in the midyear test is required to release the results produced under its severely adverse scenario, helping promote market discipline and understanding of the financial conditions and risks of individual firms, between September 15 and September 30, the Fed added. |
|
|
|
|
|
